Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TYMTRAN vs ATROPINE AND DEMEROL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TYMTRAN (pegvorhyaluronidase alfa) is a recombinant human hyaluronidase that degrades hyaluronic acid (HA) in the tumor microenvironment, reducing interstitial fluid pressure and improving drug penetration.
Atropine is an antimuscarinic agent that competitively blocks acetylcholine at muscarinic receptors, reducing secretions and gastrointestinal motility. Meperidine (Demerol) is an opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception and producing analgesia.
FDA-approved: Treatment of metastatic pancreatic ductal adenocarcinoma (m PDAC) in combination with nab-paclitaxel and gemcitabine
Preanesthetic medication to reduce secretions and prevent bradycardia,Management of moderate to severe pain (as an opioid analgesic),Off-label: treatment of opioid-induced constipation (meperidine component)
Intramuscular injection: 0.5 mg/kg body weight (maximum 25 mg per dose) administered once daily for 2 to 3 days. Oral: Not available.
Atropine 0.4 mg and Demerol (meperidine) 50-100 mg intramuscularly as preanesthetic medication 30-60 minutes before procedure.
Terminal elimination half-life is 12-15 hours in healthy adults, allowing twice-daily dosing; extended to 20-25 hours in hepatic impairment.
Atropine: 2-4 hours (terminal half-life). Demerol: 2.5-4 hours; normeperidine metabolite half-life 15-30 hours (accumulates in renal impairment).
Metabolized via proteolysis into small peptides and amino acids; not metabolized by CYP450 enzymes.
Meperidine is primarily metabolized in the liver via hydrolysis to meperidinic acid and via N-demethylation to normeperidine (active metabolite), involving CYP3A4 and CYP2B6. Atropine is metabolized in the liver via hydrolysis and glucuronidation; approximately 50% is excreted unchanged in urine.
Primarily hepatic metabolism via CYP3A4, with 70% excreted in feces as metabolites and 20% in urine as unchanged drug and metabolites.
Atropine: approximately 50% excreted unchanged in urine, remainder as metabolites (biliary and renal). Demerol (meperidine): primarily hepatic metabolism; <5% excreted unchanged in urine; metabolites (including normeperidine) excreted renally.
95% bound to albumin and alpha-1-acid glycoprotein.
Atropine: ~44% bound to albumin and alpha-1 acid glycoprotein. Demerol: ~60% bound to albumin and alpha-1 acid glycoprotein.
Volume of distribution is 0.6-0.8 L/kg, indicating moderate tissue binding.
Atropine: 1-3 L/kg (large, extensive tissue distribution). Demerol: 3-5 L/kg (large, distributes widely including CNS).
Oral bioavailability is 70% with food; decreased to 50% when taken with high-fat meal.
Atropine: oral ~10-25% (extensive first-pass metabolism). Demerol: oral ~50-60% (significant first-pass metabolism). IM/IV 100%.
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). For severe renal impairment (GFR <30 m L/min) or end-stage renal disease, avoid use due to increased risk of myopathy.
Meperidine: GFR 10-50 m L/min: administer 75% of normal dose; GFR <10 m L/min: administer 50% of normal dose and avoid due to normeperidine accumulation. Atropine: no adjustment required.
Contraindicated in Child-Pugh class C. For Child-Pugh class A or B, reduce dose by 50% and monitor creatine kinase levels.
Meperidine: Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce by 50%; Child-Pugh C: contraindicated. Atropine: caution in severe hepatic impairment.
Not recommended for children under 2 years of age. For ages 2 to 12 years, 0.5 mg/kg intramuscular injection once daily for 2 to 3 days, maximum 10 mg per dose. For ages 13 to 17 years, adult dosing applies.
Atropine 0.01 mg/kg (max 0.4 mg) and meperidine 1-2 mg/kg (max 100 mg) intramuscularly 30-60 minutes before procedure.
No specific dose adjustment, but use with caution due to increased risk of myopathy; consider lower starting dose (0.3 mg/kg) and monitor renal function and creatine kinase levels.
Reduce meperidine dose by 50% and avoid in elderly due to risk of seizures and delirium; use alternative opioids. Atropine dose unchanged but monitor for anticholinergic effects.
None.
Meperidine has a boxed warning for risk of respiratory depression, especially in elderly, cachectic, or debilitated patients, and when used with CNS depressants. Also, risk of serotonin syndrome when co-administered with serotonergic drugs, and risk of abuse, addiction, and diversion.
Hypersensitivity reactions including anaphylaxis,Hemolytic uremic syndrome (HUS) and thrombotic microangiopathy (TMA) reported in combination therapy,Hepatotoxicity: Monitor liver function,Neutropenia: Monitor complete blood counts
Respiratory depression, hypotension, bradycardia, urinary retention, constipation, serotonin syndrome, seizures (normeperidine accumulation), decreased GI motility, drug dependence, and tolerance. Use caution in elderly, renal impairment, hepatic impairment, respiratory disorders, prostatic hyperplasia, glaucoma, and with concurrent CNS depressants.
None.
Hypersensitivity to atropine or meperidine; severe asthma or COPD; acute respiratory depression; paralytic ileus; known or suspected gastrointestinal obstruction; patients receiving MAOIs (within 14 days); myasthenia gravis (relative for atropine); increased intraocular pressure (glaucoma); severe renal impairment (normeperidine accumulation).
Grapefruit juice may increase fentanyl serum concentrations and should be avoided during treatment. Alcohol consumption is contraindicated due to additive CNS depression and increased risk of respiratory depression. No other specific food interactions; however, patients should maintain a stable diet to avoid pharmacokinetic variability.
Avoid alcohol. Meperidine may interact with foods containing tyramine (aged cheeses, cured meats) in patients on MAOIs; otherwise no significant food interactions.
TYMTRAN (tyrosine kinase inhibitor) is contraindicated in pregnancy. Based on its mechanism of action and animal studies, it is expected to cause fetal harm. First trimester exposure is associated with increased risk of major congenital malformations, including cardiac and skeletal anomalies. Second and third trimester exposure may lead to fetal growth restriction, oligohydramnios, and potential fetal death. Women of childbearing potential must use effective contraception during treatment and for at least 2 weeks after the last dose.
Atropine: FDA Pregnancy Category C. Crosses placenta; may cause fetal tachycardia. Demerol (meperidine): FDA Pregnancy Category C. First trimester: limited human data; animal studies show no teratogenicity. Second trimester: no specific risks. Third trimester: use near term may cause neonatal respiratory depression, decreased Apgar scores, and withdrawal symptoms. Chronic use may lead to neonatal opioid withdrawal syndrome (NOWS).
It is unknown whether TYMTRAN is excreted in human breast milk. Due to the potential for serious adverse reactions in nursing infants, women should not breastfeed during treatment and for 2 weeks after the last dose. No M/P ratio is available.
Atropine: Excreted in breast milk in small amounts; may inhibit lactation. M/P ratio not established. Use with caution; monitor infant for anticholinergic effects (tachycardia, dry mouth). Demerol: Excreted in breast milk; relative infant dose (RID) ~0.5-0.8% of maternal weight-adjusted dose. M/P ratio 1.0-1.6. Limited data; avoid in breastfeeding due to potential neonatal sedation and respiratory depression. American Academy of Pediatrics considers meperidine compatible but caution advised.
No specific dosing adjustments have been established for TYMTRAN during pregnancy as its use is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, enhanced clearance) may theoretically reduce drug exposure, but dose modification is not recommended due to teratogenic risk. Treatment should be discontinued if pregnancy occurs.
Atropine: No specific dose adjustments recommended; increased volume of distribution may require higher doses for effect. Demerol: Increased clearance and volume of distribution in pregnancy; standard doses may be less effective. Avoid use during labor due to risk of neonatal respiratory depression; if necessary, use lowest effective dose and monitor neonate. No specific dose reduction recommended, but caution with repeated doses.
TYMTRAN (transmucosal immediate-release fentanyl) is contraindicated in opioid-naïve patients due to risk of fatal respiratory depression. Use only for breakthrough cancer pain in patients already on ≥60 mg oral morphine/day. Do not substitute on a mcg-to-mcg basis with other fentanyl products (differing bioavailability). Monitor for signs of excessive sedation and respiratory depression. Patients must have immediate access to naloxone. Instruct patients to place the entire tablet in the buccal cavity above a molar, not to suck or chew, and avoid swallowing.
Atropine and Demerol (meperidine) combination is used for pre-anesthetic medication to reduce secretions and produce sedation. Monitor for CNS depression, respiratory depression, and anticholinergic effects (tachycardia, dry mouth, urinary retention). Use cautiously in elderly, patients with COPD, asthma, or prostatic hyperplasia. Avoid in patients with MAOIs due to risk of serotonin syndrome.
Take TYMTRAN only for breakthrough cancer pain as prescribed.,Do not use in short-term pain such as after surgery or for headaches.,Place the tablet in the buccal pouch above a back tooth; allow to dissolve completely.,Do not suck, chew, or swallow the tablet; this leads to lower effectiveness and risk.,If two tablets are needed, place one on each side of the mouth.,Wait at least 4 hours before treating another episode of breakthrough pain.,Store out of reach of children and away from pets; accidental use may be fatal.,Keep naloxone available and ensure family members know how to use it.,Report severe drowsiness, confusion, slow heartbeat, or trouble breathing immediately.,Do not drink grapefruit juice while taking TYMTRAN (grapefruit juice can increase fentanyl levels).,Avoid alcohol and other central nervous system depressants (e.g., sedatives, tranquilizers).,Dispose of unused tablets via a drug take-back program or by flushing down the toilet.,Do not stop suddenly or change dose without consulting prescriber.
This medication may cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until effects are known.,Avoid alcohol and other CNS depressants while taking this medication.,Report difficulty urinating, fast heartbeat, or severe constipation to your healthcare provider.,Do not take more than prescribed; risk of dependence with long-term use.,Keep out of reach of children; may cause serious breathing problems if accidentally taken.
No interactions on record
"Rivastigmine, a reversible carbamate acetylcholinesterase inhibitor, increases synaptic acetylcholine levels, enhancing cholinergic transmission. Atropine, a competitive antagonist of muscarinic acetylcholine receptors, blocks the effects of acetylcholine at these receptors, leading to reduced parasympathetic activity. When used together, atropine can diminish the therapeutic efficacy of rivastigmine by pharmacodynamically antagonizing its cholinergic effects, particularly in the central nervous system and peripheral muscarinic receptors, potentially worsening cognitive function in Alzheimer's disease patients."
"Umeclidinium, a long-acting muscarinic antagonist (LAMA), and atropine, a non-selective muscarinic antagonist, both block the action of acetylcholine at muscarinic receptors in the parasympathetic nervous system. Their co-administration leads to additive anticholinergic effects, resulting in an increased risk of peripheral anticholinergic adverse effects such as dry mouth, blurred vision, constipation, urinary retention, and tachycardia, as well as central nervous system effects like confusion or delirium, especially in elderly patients. Clinically, this combination may also exacerbate conditions such as angle-closure glaucoma or paralytic ileus."
"Concurrent use of atropine and gallamine triethiodide results in additive antagonism at muscarinic acetylcholine receptors, leading to enhanced blockade of parasympathetic effects and increased risk of tachycardia, hypertension, and delirium. Atropine, a competitive antagonist of muscarinic receptors, counteracts the vagolytic effects of gallamine, a nondepolarizing neuromuscular blocker that also exhibits weak vagolytic activity. This pharmacodynamic interaction can cause severe sinus tachycardia, hypertension, and central anticholinergic syndrome, especially in elderly patients or those with cardiovascular disease."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TYMTRAN vs ATROPINE AND DEMEROL, answered by our medical review team.
TYMTRAN is a Opioid analgesic combination that works by TYMTRAN (pegvorhyaluronidase alfa) is a recombinant human hyaluronidase that degrades hyaluronic acid (HA) in the tumor microenvironment, reducing interstitial fluid pressure and improving drug penetration.. ATROPINE AND DEMEROL is a Opioid Analgesic Combination that works by Atropine is an antimuscarinic agent that competitively blocks acetylcholine at muscarinic receptors, reducing secretions and gastrointestinal motility. Meperidine (Demerol) is an opioid agonist that binds to mu-opioid receptors in the CNS, altering pain perception and producing analgesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TYMTRAN and ATROPINE AND DEMEROL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TYMTRAN is: Intramuscular injection: 0.5 mg/kg body weight (maximum 25 mg per dose) administered once daily for 2 to 3 days. Oral: Not available.. The standard adult dose of ATROPINE AND DEMEROL is: Atropine 0.4 mg and Demerol (meperidine) 50-100 mg intramuscularly as preanesthetic medication 30-60 minutes before procedure.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TYMTRAN and ATROPINE AND DEMEROL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TYMTRAN is classified as Category C. TYMTRAN (tyrosine kinase inhibitor) is contraindicated in pregnancy. Based on its mechanism of action and animal studies, it is expected to cause fetal harm. First trimester exposu. ATROPINE AND DEMEROL is classified as Category C. Atropine: FDA Pregnancy Category C. Crosses placenta; may cause fetal tachycardia. Demerol (meperidine): FDA Pregnancy Category C. First trimester: limited human data; animal studi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.